Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Lymphoma / Leukemia / Myeloma News

Funding Boost To Speed Up Cancer Detection For Canadian Research Network Led By University Of Toronto Chemist

Main Category: Lymphoma / Leukemia / Myeloma
Also Included In: Lung Cancer;  Biology / Biochemistry;  Medical Devices / Diagnostics
Article Date: 26 Sep 2009 - 0:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

A nanomedicine research group led by a University of Toronto chemist has received a $5-million grant from the Natural Sciences and Engineering Research Council of Canada (NSERC), giving them the green light to develop faster ways of detecting leukemia and lung cancer cells.

"This funding will lead to healthier lives for Canadians," says Gilbert Walker, a professor in U of T's Department of Chemistry and primary investigator of the Network for Bioplasmonic Systems (BiopSys). "Our first goal is to determine the presence of lung cancer at an earlier stage than is currently possible, which will permit faster screening. Our second goal is to develop similar devices for detecting leukemia that will greatly decrease the time needed for diagnosis."

The BiopSys network aims to speed up cancer diagnosis by incorporating an emerging technology known as plasmonics into existing procedures that use cancer markers found on the surfaces of cells. Plasmonics - a technique that produces waves of electrons when light hits a metal surface - offers significant opportunities for increasing the number of types of cancer markers that can be identified simultaneously.

"Bioplasmonics uses light illumination and engineers it for the extremely sensitive detection of biological molecules," says Walker. "BiopSys will develop technologies that allow for more selective detection of diseases and other health conditions that are evident on cell surfaces."

The BiopSys network is one of two U of T projects to receive a $5-million funding boost through NSERC's Strategic Research Networks program, announced today at McMaster University. The other - led by computer scientist Renée Miller, Bell Canada Chair of Information Systems at U of T - looks at developing better information management systems for business, scientific, and government organizations.

"We are delighted that two of the nine networks created today are based at U of T," says Professor Paul Young, U of T's vice-president (research). "These grants fund large-scale multi-disciplinary projects that have the potential to bring great benefit to society in the coming years, and this is exactly the kind of work that Professor Walker is leading. We will look to him and others like him who are working closely with collaborators in academia and industry for innovations that will improve the nation's economy and the quality of life of its citizens."

The network, which will receive NSERC funding of $1 million per year for five years, is unique in that it brings together experts from a wide range of disciplines and skill sets. U of T researchers in the Departments of Chemistry, Electrical and Computer Engineering, Physics and the Faculty of Medicine are involved, as well as scientists from the Universities of Ottawa, Victoria, Western Ontario and Windsor. The team also includes scientists from the École Polytechnique de Montréal and Toronto's Mt. Sinai and Princess Margaret Hospitals as well as industrial partners.

"We are extremely grateful to NSERC for its continued investment in excellence and for its support of U of T research," says University of Toronto president David Naylor. "The BiopSys network represents a unique partnership between universities, industry and government that will lead to revolutionary improvements in cancer diagnosis. The network brings together some of the best minds from a wide range of disciplines, including biochemistry, engineering and physics. Through its industrial partners, BiopSys will be able to transfer that knowledge into practice quickly, developing equipment of significant value to Canadians."

NSERC's Strategic Network grants aim to increase research and training in areas that could enhance Canada's economy, society and/or environment in the next decade.

Source:
Sean Bettam
University of Toronto


Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Chemotherapy? What Are The Side Effects Of Chemotherapy?
22 Jul 2009
Chemotherapy is the use of chemicals (medication) to treat disease - more specifically, it usually refers to the destruction of cancer cells. However, chemotherapy also includes the use of antibiotics or other medications to treat any disease...


CML Therapy Side Effects image CML Therapy Side Effects

Even "targeted" therapy for chronic myeloid leukemia is not without side effects. Some, like low blood counts, are serious. Hear how one patient, along with her oncologist, Dr. Neil Shah of UCLA, managed the side effects of her CML treatment...

Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

View more videos...